NCT01268761

GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome

Usefulness of GnRH Antagonist Administration in the Treatment of Early Ovarian Hyperstimulation Syndrome

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA · Academic / Other
• Sex: Female
• Age: 18 Years – 35 Years
• Healthy volunteers: Accepted

Summary

The aim of this study is to analyze the effectiveness of GnRh antagonist in the treatment of early ovarian hyperstimulation syndrome.

Detailed description

Ovarian hyperstimulation syndrome (OHSS) is a serious complication of ovarian stimulation protocols. Gonadotrophin-releasing hormone (GnRH) antagonist administration in the luteal phase was recently proposed as a new approach for the management of patients with established severe OHSS We analyze the response of egg donors with moderate- severe early ovarian hyperstimulation syndrome after a GnRH antagonist stimulation protocol to the administration of a daily doses of GnRH antagonist (Cetrorelix 0.25) during 7 days after the second day of oocyte retrieval compared with placebo (saline solution).

Conditions

• Ovarian Hyperstimulation Syndrome
• Effects of Gonadotropin
• Oocyte Maturation

Interventions

Type	Name	Description
DRUG	GnRH antagonist (Cetrorelix)	•GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval
DRUG	Placebo (saline solution)	• Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval

Timeline

• Start date: 2012-04-01
• Primary completion: 2013-07-01
• Completion: 2013-07-01
• First posted: 2010-12-31
• Last updated: 2013-09-19

Locations

1 site across 1 country: Spain